gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV)(gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV))

概要

基本信息

药物类型

疫苗

别名

Trimeric Glycoprotein140(Crucell Holland BV)

靶点-

作用机制

免疫刺激剂

治疗领域-

在研适应症-

非在研适应症-

原研机构

Crucell Holland B.V.

在研机构-

非在研机构

Crucell Holland B.V.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV) 相关的临床试验

NCT02304185 / Completed临床1期

A First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Dose Levels of Trimeric gp140 Protein in Healthy Adult Volunteers

The purpose of this study is to assess the safety and tolerability of 2 different dose levels of trimeric glycoprotein140 (gp140) administered as a 2-dosage regimen, intramuscularly (injection of a substance into a muscle), with and without aluminum phosphate as adjuvant in healthy human immunodeficiency virus (HIV)-uninfected participants.

开始日期2014-12-01

申办/合作机构

Crucell Holland B.V.

[+2]

100 项与 gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV) 相关的临床结果

登录后查看更多信息

100 项与 gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV) 相关的转化医学

登录后查看更多信息

100 项与 gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV) 相关的专利（医药）

登录后查看更多信息

100 项与 gp140 vaccine adjuvanted with aluminum phosphate(Crucell Holland BV) 相关的药物交易

登录后查看更多信息